| Literature DB >> 26644478 |
Abstract
Recent and rapid advances in genetic and molecular tools have brought spectacular tractability to Caenorhabditis elegans, a model that was initially prized because of its simple design and ease of imaging. C. elegans has long been a powerful model in biomedical research, and tools such as RNAi and the CRISPR/Cas9 system allow facile knockdown of genes and genome editing, respectively. These developments have created an additional opportunity to tackle one of the most debilitating burdens on global health and food security: parasitic nematodes. I review how development of nonparasitic nematodes as genetic models informs efforts to import tools into parasitic nematodes. Current tools in three commonly studied parasites (Strongyloides spp., Brugia malayi, and Ascaris suum) are described, as are tools from C. elegans that are ripe for adaptation and the benefits and barriers to doing so. These tools will enable dissection of a huge array of questions that have been all but completely impenetrable to date, allowing investigation into host-parasite and parasite-vector interactions, and the genetic basis of parasitism.Entities:
Keywords: C. elegans; CRISPR; parasitic nematode; tool development
Mesh:
Year: 2015 PMID: 26644478 PMCID: PMC4676526 DOI: 10.1534/genetics.115.182717
Source DB: PubMed Journal: Genetics ISSN: 0016-6731 Impact factor: 4.562
Figure 1CRISPR/Cas9 editing. (A) The Cas9:sgRNA complex scans the genome searching for “NGG” PAM sequences (blue text). The 20 bp at the 5′ end of the sgRNA are homologous to the 20 bp 5′ to the PAM in the genomic target site, and the sgRNA pairs with the complementary strand in the genomic target sequence. The PAM sequence instructs Cas9 to make a DNA double-stranded break (DSB) three to four nucleotides 5′ to the PAM. (B) A Cas9-induced DSB can be repaired through error-prone nonhomologous end joining (NHEJ) or error-free homologous recombination (HR) pathways. NHEJ can be used for gene inactivation, as it produces small, random insertion and deletion mutations at the DSB site. By supplying repair templates with homology arms flanking the break site, one can use HR to precisely delete sequences, insert epitopes, or introduce point mutations. To recover HR-mediated knock-ins, one must often either screen large numbers of cells/animals or use positive selection/co-CRISPR approaches; HR is typically less efficient at producing edits compared to NHEJ.
Strongyloides spp. overview
| Lifecycle | Health burden | Transgenesis | Genetic tools |
|---|---|---|---|
| • iL3 larvae penetrate skin, make it to small intestine | • Estimated 30–100 million infected | • Gonadal microinjection of adults ( | • Promoter:fluorescent protein reporters ( |
| • Adults produce larvae that are shed in stool | • Asymptomatic to mild manifestations in skin, lung, and intestines | • Transposons for insertional mutagenesis and stable transformation ( | |
| • Larvae excreted into the environment can either develop directly into iL3 or enter a free-living stage, developing to adults outside the host | • Infection can be life threatening in immunocompromised individuals | ||
| • |
B. malayi overview
| Lifecycle | Health burden | Transgenesis | Genetic tools |
|---|---|---|---|
| • L1–L3 in mosquito, L4–adult in mammalian host | • 120 million with lymphatic filariasis | • Bombardment of embryos and adult females ( | • Luciferase reporters in embryos and L3s ( |
| • Adults live in lymphatic vessels | • | • Gonadal microinjection of adult females ( | • Immunofluorescence ( |
| • Adult females can release up to 10,000 of specialized L1 larvae (microfilariae) per day | • Disfiguring lymphodema, elephantiasis, and scrotal swelling | • Calcium phosphate precipitate-mediated transformation of L3s | • RNAi: on adult females to knock down embryo gene expression ( |
Ascaris spp. overview
| Lifecycle | Health burden | Transgenesis | Genetic tools |
|---|---|---|---|
| • After ingestion of infective eggs, larvae hatch, penetrate intestine wall, and migrate to lungs by way of liver | • Estimated 800–1000 million infected with | • Bombardment in | • Whole |
| • Larvae develop further, are coughed up, swallowed, and develop to adults in the small intestine | • Asymptomatic to light abdominal discomfort | • RNAi by microinjection into | |
| • Adult females can release up to 200,000 eggs per day | • Heavy infections can cause intestinal blockage and stunt child development and growth | ||
Figure 2Recommended pipeline for technology import into parasitic nematodes. One should start with a parasitic nematode species that has an annotated genome or transcriptome or generate these datasets. For the described genetic tools, a method of transgenesis is a prerequisite. Promoter:FP reporters should be used to characterize regulatory elements, and monitor gene expression, temporally and spatially. The regulatory elements characterized through the FP reporters are useful for development of selection systems and CRISPR editing approaches. Positive selection systems, such as drug resistance or FP reporter expression, help identify transgenic animals. Drug selection cassettes are preferable, as they could allow for in vivo selection of transgenic parasites in host animals. For CRISPR approaches, it is best to start with activation or repression of gene expression using CRISPRa or CRISPRi, respectively, or generation of indel mutations using somatic CRISPR editing. These approaches should work in first generation transgenic animals, circumventing issues with requisite host passage. If these methods are robust, the lifecycle can be maintained, and once a positive selection system is in place, one can attempt to generate stable knockouts or knockins. A gene drive system is recommended, with appropriate safeguards, to create homozygotes in first generation transgenics, and subsequently in any genetic background to which the transgene is introduced.
Current range of CRISPR/Cas9 editing efficiencies in C. elegans
| Edit type | Selection | No. injected | Success rate |
|---|---|---|---|
| Indels | No selection, 3′-GG sgRNAs | 7–33 | 10–72% of screened transgenic marker positive F1 ( |
| Indels | co-CRISPR | 20–40 | 36–88% of screened co-CRISPR marker positive F1 ( |
| Small knockins (point mutations, stop codons, epitopes) | co-CRISPR | 20–40 | 8–50% of screened co-CRISPR marker positive F1 ( |
| Small knockins (point mutations, stop codons, epitopes) | co-CRISPR, 3′-GG sgRNAs | 20–40 | 30–63% of screened co-CRISPR marker positive F1 ( |
| GFP-sized knockin | co-CRISPR | 17–40 | 50% of screened co-CRISPR marker positive F1 ( |
| GFP-sized knockin | co-CRISPR, Cas9 RNP | 10–20 | 2–80% of screened co-CRISPR marker positive F1 ( |
| GFP-sized knockin | Drug selection | 6–90 | 0–25% of injected parental animal (due to selection, do not know how many F1 are screened ( |